Please login to the form below

Not currently logged in
Email:
Password:

US Congress

This page shows the latest US Congress news and features for those working in and with pharma, biotech and healthcare.

FDA moves to tackle orphan designation backlog

FDA moves to tackle orphan designation backlog

FDA moves to tackle orphan designation backlog. Some 200 requests are awaiting review by the US regulator. ... Congress gave us tools to incentivise the development of novel therapies for rare diseases and we intend to use these resources to their

Latest news

  • The tribe has spoken The tribe has spoken

    Reality TV has given us countless catchphrases and memorable pop culture idioms and Jeff Probst's final words to the ousted Survivor competitors - “ the tribe has spoken, it's time for ... Forget, for a moment, about the fact that for this to happen it

  • Alexion's rare bone disorder therapy rejected by NICE Alexion's rare bone disorder therapy rejected by NICE

    In the US the drug has been priced at an average $285, 000 a year - well below the level expected by analysts - with some suggesting the company may have been spooked ... The US decision may signal that Alexion is prepared to be flexible on Strensiq's

  • Who is the marketer of the future? Who is the marketer of the future?

    In the past getting 1-5 articles a year published and obtaining good congress coverage in Europe and US was considered successful. ... It is therefore essential for us to have resources and people dedicated to developing content constantly and who are

  • US talks tough on 'unpatriotic' tax inversion deals US talks tough on 'unpatriotic' tax inversion deals

    US talks tough on 'unpatriotic' tax inversion deals. Treasury looks to 'meaningfully reduce' tax benefits of such manoeuvres. ... companies overseas in order to shift their domiciles and sidestep high US corporation tax rates.

  • Allergan wields axe to fend off Valeant Allergan wields axe to fend off Valeant

    Valeant is also going on the offensive in its pursuit of Allergan, however, and filed complaints in the US and Canada this week over statements made by Allergan which suggested its ... The US Congress, "watching the mass exodus of US companies to lower

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Latest Intelligence

  • Attracting doctors to low-demand specialties Attracting doctors to low-demand specialties

    A US survey that has been undertaken every year since the early 1990s provides some illumination as to the specialties that residents and fellows completing their training in New York State ... A brief glance at the programme for the major US haematology

More from intelligence
Approximately 0 fully matching, plus 1 partially matching documents found.

Latest from PMHub

  • EULAR Annual European Congress of Rheumatology 2017

    EULAR Annual European Congress of Rheumatology 2017. Join us at EULAR Congress 2017 in Madrid, 14-17 June. ... We are delighted to be attending and presenting at this year’ s EULAR Annual European Congress of Rheumatology in June.

  • Attracting doctors to low-demand specialties: A role for industry?

    A US survey that has been undertaken every year since the early 1990s provides some illumination as to the specialties that residents and fellows completing their training in New York State ... A brief glance at the programme for the major US haematology

  • Research Partnership

    Research Partnership is today expanding its US operations across both the West and East Coast. ... Visit us on stand number 14. Join us at EULAR Congress 2017 in Madrid, 14-17 June.

More from PMHub
Approximately 0 fully matching, plus 3 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Makara Health

Independent healthcare communications agency with a passion to develop inspirational ideas that create sustained and positive change. Whether it is...

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics